Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q4 FY26 Earnings Presentation
17 slides from Zydus Lifesciences's earnings presentation, May 19, 2026
Slide 1: Exchange filing cover letter: Investor Presentation
May 19, 2026 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentation Ref.: Disclosure unde
Slide 2: Earnings Presentation: Q4 & Full Year FY26
Zydus Lifesciences Limited Earnings Presentation: Q4 & Full Year FY26 19th May, 2026 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general
Slide 4: Q4 FY26: At a Glance
Q4 FY26: At a Glance Revenues from Highlights of Q4 FY26 R&D Operations ❑ Total revenues grew 16% YoY. Rs. 75,870 mn Rs. 6,982 mn ❑ Within Pharmaceutical business, 16% YoY 9.2% of revenues ➢ India branded formulations sustained the growth momentum and outpaced the market growth for yet another quart
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 74.0% 73.2% 74.0% 72.7% 73.1% 75,870 2,71,484 56,107 1,98,558 65,279 68,645 2,32,415 48,308 50,282 1,69,035 Q4FY25 Q3FY26 Q4FY26 FY25 FY26 Q4FY25 Q3FY26 Q4FY26 FY25 FY26 Total R&D (Rs. mn) and % to Revenues
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) PAT ex. Exceptional (Rs. mn) Organic Capex (Rs. mn) 15,929 54,564 4,637 17145 47,451 13,905 3,577 11,105 3,202 12140 Q4FY25 Q3FY26 Q4FY26 FY25 FY26 Q4FY25 Q3FY26 Q4FY26 FY25 FY26 Net Debt to EBITDA (x) Net Working Capital* (Rs. mn) 0.50 81,987 0.28 0.34 72,513 75,938 57,4
Slide 7: India Formulations business
India Formulations business Sustained market outperformance led by chronic portfolio Highlights for the quarter India Formulations Sales Q4 FY26 Revenue India Formulations Sales ▪ Branded business grew faster than the market with (Rs. mn) Contribution (Rs. mn) 15% YoY growth. 17,094 17,528 65,740 15
Slide 8: North America Formulations business
North America Formulations business Base business volume expansion and new launches drove the growth Highlights for the quarter North America Formulations Q4 FY26 Revenue North America US Generics Sales (Rs. mn) Contribution Formulations Sales (Rs. mn) ▪ Ranked 3rd among US generic companies based o
Slide 9: International Markets Formulations business
International Markets Formulations business Strong growth : Resilient demand across markets Highlights for the quarter EM & EU Formulations Sales Q4 FY26 Revenue EM & EU Formulations Contribution Sales (Rs. mn) (Rs. mn) ▪ Growth was broad based in both Emerging markets 7,881 8,041 30,700 and Europe
Slide 10: Consumer Wellness
Consumer Wellness Strengthening international presence through CCL acquisition Highlights for the quarter Consumer Wellness Sales Q4 FY26 Revenue Consumer Wellness (Rs. mn) Contribution Sales (Rs. mn) ▪ In domestic business, retained leadership position 14,633 39,134 across most product categories.
Slide 11: Updates on Innovation
Updates on Innovation NCE Research • Desidustat tablets, which was licensed to China Medical System Holdings in 2020, received approval from the Chinese regulator for the treatment of renal anemia. • USFDA granted ODD status to Desidustat for the treatment of sickle cell disease. • Received approval
Slide 12: Zydus at a Glance
Zydus at a Glance 3rd 8 +$3 R&D Centers Largest generic Co. in US For NCE, APIs, Generics, Vaccines Global Revenues1 bn in terms of prescription3 Biosimilars, Wellness and Med-tech products Among 1st Revenues from Branded Approved product for >50% In ~55% of product Business (Pharmaceutical, Top 3 f
Slide 13: ESG Rankings
ESG Rankings 2023 2024 2025 62 78 84 Higher the Better 2024 2025 66 68 Higher the Better Strong Category: An ESG leader who demonstrates strong track record in managing material ESG risks through a robust risk management framework 2024 2025 2026 ❑ ZLL is ranked among the top 10% in the pharmaceutica
Slide 14: ESG Performance
ESG Performance Climate Change Water (GHG Emissions) Management Net Water Neutral by 2028 Net Carbon Neutral by 2035 Creation of water recharge structures in progress 50% energy requirements from renewable sources by 2030 >66% recycle and reuse of treated wastewater 37% of renewable energy in the to
Slide 15: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) Q4 Q4 YoY Q3 QoQ YoY Rs. mn FY26 FY25 FY26 FY25 gr. FY26 gr. gr. Total Income from Ops. 75,870 65,279 16.2% 68,645 10.5% 2,71,484 2,32,415 16.8% Gross Contribution (GC) 56,107 48,308 16.1% 50,282 11.6% 1,98,558 1,69,035 17.5% Gross Margin % 74.0% 74.0% 7
Slide 16: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations Q4 Q4 YoY YoY Rs. mn FY26 FY25 FY26 FY25 gr. % gr. % A. On operating transactions (above EBITDA line) -6,052 504 -1300.8% -11,976 -1,451 -725.2% a. Included in COGS 398 110 262% 830 183 353.7% b. Part of other operating expenses (shown separately) -6,449 394 -17
Slide 17: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-79-48040969 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C